IP Library Granted Patent US 8,080,520
Granted Patent B2
US 8,080,520 · App. 12/506,139 · Granted Dec 20, 2011

Composition and method for treating iron deficiency anemia

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,080,520
App. No.
12/506,139
Granted
Dec 20, 2011
Kind
B2
Abstract

A composition comprising heme iron and/or heme iron polypeptide in combination with ionic iron(s) and/or chelated iron(s). Administration of effective dosages of the present composition provides a method for treating and/or preventing iron deficiency anemia, and the physiological, biochemical, morphological, and behavioral manifestations symptomatic of same.

Claims (36)

1. A pharmaceutical composition for treating iron deficiency or iron deficiency anemia in a human, consisting essentially of:

heme iron polypeptide; and,

at least one chelated iron selected from the group consisting of iron polysaccharide, iron bisglycinate, and iron proteinate, and combinations thereof,

wherein said pharmaceutical composition is formulated for oral administration, and is contained within a unit selected from the group consisting of a tablet and a capsule.

2. A pharmaceutical composition for treating iron deficiency or iron deficiency anemia in a human, consisting essentially of:

heme iron polypeptide; and,

iron polysaccharide,

wherein said pharmaceutical composition is formulated for oral administration, and is contained within a unit selected from the group consisting of a tablet and a capsule.

3. A pharmaceutical composition for treating iron deficiency or iron deficiency anemia in a human, consisting essentially of:

heme iron polypeptide;

iron polysaccharide; and,

at least one vitamin selected from the group consisting of folic acid, vitamin B6, vitamin B12, and combinations thereof,

wherein said pharmaceutical composition is formulated for oral administration, and is contained within a unit selected from the group consisting of a tablet and a capsule.

4. A pharmaceutical composition for treating iron deficiency or iron deficiency anemia in a human, consisting essentially of:

heme iron polypeptide;

at least one chelated iron selected from the group consisting of iron polysaccharide, iron bisglycinate, and iron proteinate, and combinations thereof; and,

at least one vitamin selected from the group consisting of folic acid, vitamin B6, vitamin B12, and combinations thereof,

wherein said pharmaceutical composition is formulated for oral administration, and is contained within a unit selected from the group consisting of a tablet and a capsule.

5. A pharmaceutical composition for nutritional supplementation in a prenatal or lactating human female, consisting essentially of:

heme iron polypeptide;

iron polysaccharide; and,

at least one nutrient selected from the group consisting of vitamins, minerals, and a combination thereof,

wherein said pharmaceutical composition is formulated for oral administration, and is contained within a unit selected from the group consisting of a tablet and a capsule.

6. A pharmaceutical composition for nutritional supplementation in a prenatal or lactating human female, consisting essentially of:

heme iron polypeptide;

at least one chelated iron selected from the group consisting of iron polysaccharide, iron bisglycinate, and iron proteinate, and combinations thereof; and,

at least one nutrient selected from the group consisting of vitamins, minerals, and a combination thereof,

wherein said pharmaceutical composition is formulated for oral administration, and is contained within a unit selected from the group consisting of a tablet and a capsule.

7. A pharmaceutical composition for nutritional supplementation in a prenatal or lactating human female, consisting essentially of:

heme iron polypeptide; and,

iron polysaccharide,

wherein said pharmaceutical composition is formulated for oral administration, and is contained within a capsule, said capsule further including additional nutrients for the prenatal or lactating human female.

8. A pharmaceutical composition for nutritional supplementation in a prenatal or lactating human female, consisting essentially of:

heme iron polypeptide; and,

at least one chelated iron selected from the group consisting of iron polysaccharide, iron bisglycinate, and iron proteinate, and combinations thereof;

wherein said pharmaceutical composition is formulated for oral administration, and is contained within a capsule, said capsule further including additional nutrients for the prenatal or lactating human female.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2021
From: MEDA AB; ALAVEN PHARMACEUTICAL LLC
To: NURYA BRANDS, INC.
Reel/Frame 056210/0968 →
RELEASE OF SECURITY INTEREST Recorded Oct 7, 2010
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT
To: ALAVEN PHARMACEUTICAL LLC
Reel/Frame 025105/0550 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2010
From: VENKATARAMAN, BALA
To: ALAVEN PHARMACEUTICAL, LLC
Reel/Frame 023892/0155 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2010
From: GUTHRIE, MICHAEL
To: COLORADO BIOLABS, INC.
Reel/Frame 023892/0173 →
THIRD AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Oct 15, 2009
From: ALAVEN PHARMACEUTICAL LLC
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT
Reel/Frame 023379/0789 →